Breast Cancer Liquid Biopsy Market Revenue Worth USD 5.14 Million in 2032

Breast cancer is one of the most prevalent cancers among women globally. The early detection and diagnosis of breast cancer are essential for effective treatment and improved patient outcomes. Liquid biopsy has emerged as a promising non-invasive diagnostic tool that enables the detection of cancer-specific biomarkers in body fluids such as blood. The Integrated Breast Cancer Liquid Biopsy Market is a rapidly growing sector that aims to improve the early detection and monitoring of breast cancer through liquid biopsy testing.

One of the significant drivers of the Integrated Breast Cancer Liquid Biopsy Market is the increasing prevalence of breast cancer worldwide. The global breast cancer liquid biopsy market size reached USD 5.14 Billion in 2022 and is expected to register a revenue CAGR of 22.7% during the forecast period, according to latest analysis by Emergen Research. The rising incidence of breast cancer is fueling the demand for innovative diagnostic tools such as liquid biopsy, which can help detect cancer in its early stages and improve patient outcomes.

factor driving the growth of the Integrated Breast Cancer Liquid Biopsy Market is the increasing adoption of liquid biopsy testing by healthcare professionals. Liquid biopsy offers several advantages over traditional tissue biopsy, including reduced invasiveness, faster turnaround times, and the ability to monitor cancer progression and treatment response over time. These benefits are driving the adoption of liquid biopsy testing in clinical practice, particularly for breast cancer patients.

the numerous growth drivers, the Integrated Breast Cancer Liquid Biopsy Market faces several challenges that may hinder its growth. One of the significant challenges is the lack of standardization in liquid biopsy testing protocols. The absence of standardized testing protocols makes it challenging to compare results across different laboratories and may affect the accuracy and reliability of liquid biopsy testing.

Government organizations are also playing a critical role in driving the growth of the Integrated Breast Cancer Liquid Biopsy Market. For example, the US Food and Drug Administration (FDA) has recently approved several liquid biopsy tests for the detection of breast cancer biomarkers, including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). The FDA's approval of these tests has helped to increase the availability and adoption of liquid biopsy testing in clinical practice.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/1816

Major Companies and Competitive Landscape:

Menarini Group, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., QIAGEN, Biocept, Inc., Sysmex Corporation, Fluxion Biosciences, Inc., Epic Sciences, Inc., and Thermo Fisher Scientific Inc.

1. F. Hoffmann-La Roche Ltd: Roche is a leading player in the breast cancer liquid biopsy market, offering several diagnostic tests, including the cobas® EGFR Mutation Test v2, cobas® KRAS Mutation Test, and the cobas® PIK3CA Mutation Test. The company also offers the Elecsys® HER2 total assay, which is a blood test that helps to identify HER2-positive breast cancer.

2. QIAGEN: QIAGEN is a leading provider of liquid biopsy technologies, offering several diagnostic tests for breast cancer, including the QIAsure Methylation Test and the QIAGEN Clinical Insight (QCI) Interpret NGS Analysis and Reporting Services. The company also recently launched the QIAseq cfDNA Tumor Panel, a next-generation sequencing (NGS) solution for the analysis of cell-free DNA (cfDNA) in liquid biopsy samples.

3. Bio-Rad Laboratories, Inc.: Bio-Rad is a leading provider of diagnostic and research tools for the life sciences industry, including several liquid biopsy technologies. The company offers the droplet digital PCR (ddPCR) platform, which enables highly sensitive and precise detection of cancer biomarkers in liquid biopsy samples. Bio-Rad also recently launched the QXDx AutoDG ddPCR System, a fully automated system for the detection of cancer biomarkers in liquid biopsy samples.

4. Guardant Health, Inc.: Guardant Health is a leading provider of liquid biopsy technologies, offering several diagnostic tests for breast cancer, including the Guardant360® and GuardantOMNI® assays. These tests use NGS technology to analyze ctDNA in liquid biopsy samples and help to identify actionable mutations in breast cancer patients.

5. Thermo Fisher Scientific Inc.: Thermo Fisher is a leading provider of life sciences research tools and diagnostics, including several liquid biopsy technologies. The company offers the Oncomine™ Breast cfDNA Assay, which is an NGS-based assay for the detection of ctDNA in liquid biopsy samples. Thermo Fisher also offers the Ion Torrent™ Genexus System, a fully automated platform for the detection of cancer biomarkers in liquid biopsy samples..

In conclusion, the Breast Cancer Liquid Biopsy Market is a highly competitive and rapidly growing sector with several established and emerging players. The market is characterized by intense competition, technological advancements, and increasing investments in R&D. Companies that can develop innovative liquid biopsy technologies with high sensitivity, specificity, and reliability are expected to gain a competitive edge in the market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1816

Segmentation Insights for Breast Cancer Liquid Biopsy Market Report:

Emergen Research has conducted a segmentation analysis of the global breast cancer liquid biopsy market based on the application, circulating biomarker, and region. According to the report, the market is segmented based on the application outlook into early detection/screening, diagnosis, and others. The market size and revenue generated by each segment from 2019 to 2032 are also provided in USD billion. The early detection/screening segment is expected to witness significant growth during the forecast period due to the increasing prevalence of breast cancer and the need for early diagnosis and treatment.

The circulating biomarker outlook of the breast cancer liquid biopsy market is also segmented into circulating tumor cells, extracellular vesicles, and others. The revenue generated by each segment is provided in USD billion for the period 2019 to 2032. Circulating tumor cells are expected to hold the largest market share during the forecast period due to their ability to provide information about the metastatic potential of cancer cells and their response to treatment.

Geographically, the global breast cancer liquid biopsy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report provides a detailed analysis of the market share, revenue, and growth rate of each region from 2019 to 2032. North America is expected to dominate the market during the forecast period due to the increasing prevalence of breast cancer and the availability of advanced healthcare infrastructure.

In conclusion, the global breast cancer liquid biopsy market is segmented based on the application outlook into early detection/screening, diagnosis, and others, and the circulating biomarker outlook into circulating tumor cells, extracellular vesicles, and others. The market is also segmented based on region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report provides a comprehensive analysis of the market size, revenue, and growth rate of each segment from 2019 to 2032, which will help stakeholders and investors make informed decisions.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/breast-cancer-liquid-biopsy-market

Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions.

This release was published on openPR.